News

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground.

LOGIPIX, a global leader in high-resolution intelligent computer vision solutions, was chosen after a rigorous selection process for its advanced capabilities and track record of successful implementations in high-volume commercial airside environments, such as LaGuardia Airport.

The Virtual Ramp Control System will leverage LOGIPIX’ innovative multi-sensor panoramic video technology and Airside Augmented Reality Solution (LAARS) software to provide monitoring and analysis of ground activities with live object classification and tracking, supporting the Terminal 6 gate operations center. Integrating high-resolution cameras, intelligent AI analytics, and advanced control features, the system will enhance the efficiency of aircraft management with real time decision-making support and improved situational awareness.

“We are thrilled to work with JFK Millennium Partners to deploy our Virtual Ramp Control System,” said Mike Broggie, President of LOGIPIX US Corporation. “This collaboration underscores our commitment to provide cutting-edge solutions that address the evolving needs of modern airports, and we are confident that our technology will contribute to JFK’s innovative transformation into a world-class facility.”

Implementation of the Virtual Ramp Control System will occur in two phases during construction of Terminal 6.

Recent News

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

12/03/2024

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint. The report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” analyzes the sector’s economic impact via employment, overall